Trichosporon austroamericanum
| Trichosporon austroamericanum | |
|---|---|
| Scientific classification | |
| Kingdom: | Fungi |
| Division: | Basidiomycota |
| Class: | Tremellomycetes |
| Order: | Trichosporonales |
| Family: | Trichosporonaceae |
| Genus: | Trichosporon |
| Species: | T. austroamericanum |
| Binomial name | |
| Trichosporon austroamericanum Francisco et al., 2024 | |
Trichosporon austroamericanum is an anamorphic basidiomycetous yeast species with opportunistic pathogenic potential, formally described in 2024.[1] It was long confused with Trichosporon inkin due to their close phylogenetic relationship,[1] but is now recognized as the second most frequently implicated Trichosporon species in invasive trichosporonosis in France.[2]
Etymology
The species name austroamericanum derives from the Latin austro- ("southern") and americanum ("American"), referring to South America, where the first identified strain originated.[1]
History
Discovery
The first strain of T. austroamericanum was isolated in 2013 in Brazil from the urine of a 15-year-old renal transplant patient undergoing surgery for a urinary fistula.[1] The isolate was initially identified as Trichosporon inkin due to strong phenotypic and molecular similarity between the two species.[1]
Recognition as a distinct species
In 2024, Francisco et al. formally described T. austroamericanum as a new species based on detailed phylogenetic analysis.[1] The historical confusion with T. inkin is explained by their genetic proximity, which makes differentiation difficult using routine molecular tools.[1]
In 2025, the first complete genome sequencing of T. austroamericanum (type strain CBS 17435) was performed using long-read Nanopore sequencing technology.[3] Average Nucleotide Identity (ANI) between T. austroamericanum and T. inkin was 84.64%, well below the 95% threshold commonly used for species delimitation, confirming that they are distinct species.[3] These findings were supported by comparative genomic analysis of three Japanese clinical isolates.[4]
Description
Morphology
T. austroamericanum is an anamorphic (asexual) fungus that presents as a yeast. Like other species of Trichosporon, it produces arthroconidia through hyphal fragmentation.[1] Its morphology is very similar to that of T. inkin, making differentiation difficult using conventional microscopic or macroscopic examination.[1]
Differentiation from T. inkin
Differentiation relies mainly on molecular methods, including sequencing of the IGS1 (Intergenic Spacer 1) region and multilocus phylogenetic analysis. Phenotypic differences include thermotolerance (growth at 45 °C), absence of growth in media containing 50% glucose, and inability to utilize succinate or citrate.[1]
Ecology
The environmental reservoir of T. austroamericanum remains unknown.[1] Like other Trichosporon species, it is part of the transient human microbiota and may colonize the skin and gastrointestinal tract without causing disease in immunocompetent individuals.[1]
Epidemiology
Global distribution
Strains of T. austroamericanum—initially misidentified as T. inkin—have been reported worldwide, suggesting a cosmopolitan distribution:[1][2]
Prevalence in France
A French study (2002–2022) found that T. austroamericanum accounted for 22.8% of Trichosporon isolates, making it the second most frequently identified species in the country.[2]
Another study reidentified 17 isolates initially classified as T. inkin as T. austroamericanum using IGS1 sequencing.[5]
Clinical characteristics
At-risk populations
Invasive infections mainly occur in immunocompromised patients or those undergoing major surgery.[2] In a French cohort (21 cases):
- 86.4% were male
- 36.4% had recent surgery
- 36.4% were solid organ transplant recipients
Clinical manifestations
Reported infection sites include:[2]
- fungemia: 68.2%
- bone infections: 18.2%
- cutaneous infections: 4.5%
Prognosis
The 30-day mortality rate was 22.7% in the studied cohort.[2]
European surgical context
A fatal case following heart transplantation has been reported, initially misidentified as T. inkin.[5] Literature review highlights similar invasive infections after major thoracic surgeries in Europe.[5]
Persistent fever in immunocompromised patients receiving echinocandin therapy may suggest infection with resistant Trichosporon species.[5]
Virulence factors
Identified virulence factors include:[4]
- biofilm formation and protease production
- presence of a Zn(II)2Cys6 transcription factor gene (also found in Trichosporon asahii)
- high virulence in Galleria mellonella models, comparable to T. asahii
Diagnosis
Identification is challenging due to frequent confusion with T. inkin.[1] Reliable methods include:
Antifungal susceptibility
Antifungal susceptibility (EUCAST, 21 isolates):[2]
| Antifungal | MIC50 (mg/L) | MIC90 (mg/L) | Range (mg/L) |
|---|---|---|---|
| Voriconazole | 0.03 | 0.06 | <0.015–0.125 |
| Posaconazole | 0.06 | 0.25 | <0.015–0.25 |
| Amphotericin B | 0.25 | 1 | 0.06–2 |
| Flucytosine | >64 | >64 | 64–>64 |
| Fluconazole | 0.5 | 4 | 0.25–4 |
T. austroamericanum is intrinsically resistant to echinocandins. New-generation triazoles (voriconazole, posaconazole, isavuconazole) show the best in vitro activity.[2]
Voriconazole is the recommended first-line treatment.[2]
References
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Francisco, E.C.; Desnos-Ollivier, M.; Dieleman, C.; Boekhout, T.; Santos, D.W.C.L.; Medina-Pestana, J.O.; Colombo, A.L.; Hagen, F. (2024). "Unveiling Trichosporon austroamericanum sp. nov.: A novel emerging opportunistic basidiomycetous yeast species". Mycopathologia. 189 (3): 43. doi:10.1007/s11046-024-00851-4. PMC 11074034. PMID 38709328.
- 1 2 3 4 5 6 7 8 9 10 11 Desnos-Ollivier, M. (2026). "Clinical manifestations of emerging Trichosporon spp. infections, France". Emerging Infectious Diseases. 32 (1): 93–102. doi:10.3201/eid3201.250504. PMC 12870045. PMID 41612557.
- 1 2 3 Francisco, E.C.; Desnos-Ollivier, M.; Gerrits van den Ende, B.; Hagen, F. (2025). "De novo genome assembly and comparative genome analysis of the novel human fungal pathogen Trichosporon austroamericanum type-strain CBS 17435". Mycopathologia. 190 (2): 33. doi:10.1007/s11046-025-00942-w. PMC 11971232. PMID 40183900.
- 1 2 Horiguchi, T.; Umeyama, T.; Tomuro, H. (2025). "Whole-genome sequencing and comparative genomic analysis of three clinical bloodstream infection isolates of Trichosporon austroamericanum". Journal of Fungi. 11 (5): 401. doi:10.3390/jof11050401. PMC 12113199. PMID 40422735.
- 1 2 3 4 5 Cordier, C. (2026). "Invasive Trichosporon austroamericanum infection following heart transplantation: a case report and literature review of Trichosporon inkin sensu lato infections after thoracic surgery". Journal of Medical Mycology. 36 (1) 101600. doi:10.1016/j.mycmed.2026.101600. PMID 41547089.